Hemostemix Inc. (CVE:HEM – Get Free Report) was down 19.4% on Thursday . The stock traded as low as C$0.14 and last traded at C$0.15. Approximately 519,694 shares traded hands during mid-day trading, a decline of 1% from the average daily volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Price Performance
The company has a 50-day moving average price of C$0.20 and a two-hundred day moving average price of C$0.12. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company has a market cap of C$21.13 million, a PE ratio of -4.23 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Consumer Staples Stocks, Explained
- SoundHound AI Stock at a Crossroads—Is a Bottom in Sight?
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Hershey’s Sweet Comeback: Why Investors Are Taking Notice
- Options Trading – Understanding Strike Price
- 3 Reasons Occidental Petroleum Will Gush Higher in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
